CD34⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg^null mice

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–13. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society. 2007;17(1):21–31. doi:10.1111/j.1525-1438.2007.00826.x.
   PubMed Web of Science ®Google Scholar
• Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, et al. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-Restricted HER-2/ neu-specific immunity. Cancer Res. 2006;66(12):6387–6394. doi:10.1158/0008-5472.CAN-06-0029.
   PubMed Web of Science ®Google Scholar
• Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I, et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunology, Immunotherapy: CII. 2009;58(5):641–652. doi:10.1007/s00262-008-0585-3.
   PubMed Web of Science ®Google Scholar
• Felices M, Chu S, Kodal B, Bendzick L, Ryan C, Lenvik AJ, Boylan KLM, Wong HC, Skubitz APN, Miller JS, et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol. 2017;145(3):453–461. doi:10.1016/j.ygyno.2017.02.028.
   PubMed Web of Science ®Google Scholar
• Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H. Umbilical cord blood CD34(+) progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg(null) mice. Oncoimmunology. 2017;6(8):e1320630. doi:10.1080/2162402X.2017.1320630
   Google Scholar
• Fruscella E, Gallo D, Ferrandina G, D’Agostino G, Scambia G. Gemcitabine: current role and future options in the treatment of ovarian cancer. Crit Rev Oncol Hematol. 2003;48(1):360–371. doi:10.1016/S1040-8428(03)00119-7.
   Web of Science ®Google Scholar
• Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, et al. Contrasting effects of the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells. PloS One. 2015;10(10):e0139809. doi:10.1371/journal.pone.0139809.
   PubMed Web of Science ®Google Scholar
• Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM et al. Gemcitabine and Paclitaxel: pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung Cancer . Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1999;17(7):2190–2197. doi:10.1200/JCO.1999.17.7.2190.
   Google Scholar
• Gravett AM, Dalgleish AG, Copier J. In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells. Sci Rep. 2019;9(1):1544. doi:10.1038/s41598-018-38190-2.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Ogino T, Nagamatsu I, Katano M. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. Anticancer Res. 2011;31(7):2505–2510
   Google Scholar
• Miyashita T, Miki K, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed AK, et al. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Clin Exp Med. 2017;17(1):19–31. doi:10.1007/s10238-015-0394-x.
   PubMed Web of Science ®Google Scholar
• Xie X, Zhou Y, Wang X, Guo J, Li J, Fan H, Dou J, Shen B, Zhou C. Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo. Carbohydr Polym. 2017;173:360–371. doi:10.1016/j.carbpol.2017.06.024.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tomogane M, Miyashita M, Ukimura O, Ashihara E. Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model. Oncoimmunology. 2018;7(5):e1424671. doi:10.1080/2162402X.2018.1424671.
   PubMed Web of Science ®Google Scholar
• Gurlevik E, Fleischmann-Mundt B, Brooks J, Demir IE, Steiger K, Ribback S, Yevsa T, Woller N, Kloos A, Ostroumov D, et al. Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells. Gastroenterology. 2016;151(2):338–50.e7. doi:10.1053/j.gastro.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, de Jonge P, Evert JSH, van der Waart AB, Cany J, Safrit JT, Lee JH et al. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34(+) progenitor-derived NK cells. Cancer Immunology, Immunotherapy: CII. 2021;70(5):1305–1321. doi:10.1007/s00262-020-02749-8
   Google Scholar
• Grobben Y, De Man J, Van Doornmalen AM, Muller M, Willemsen-Seegers N, Vu-Pham D, Mulder WR, Prinsen MBW, De Wit J, Sterrenburg JG, et al. Targeting Indoleamine 2,3-Dioxygenase in cancer models using the novel small molecule inhibitor NTRC 3883-0. Front Immunol. 2020;11:609490. doi:10.3389/fimmu.2020.609490.
   PubMed Web of Science ®Google Scholar
• Abushahin F, Rose PG. Role of gemcitabine in the treatment of ovarian cancer. Women’s Health. 2007;3(3):279–290. doi:10.2217/17455057.3.3.279.
   PubMedGoogle Scholar
• Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, Eksborg S, Klein E, Skribek H, Szekely L, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther. 2007;6(2):644–654. doi:10.1158/1535-7163.MCT-06-0358.
   PubMed Web of Science ®Google Scholar
• Lanz C, Früh M, Thormann W, Cerny T, Lauterburg BH. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. J Sep Sci. 2007;30(12):1811–1820. doi:10.1002/jssc.200600534.
   PubMed Web of Science ®Google Scholar
• Conte PF, Gennari A, Donati S, Salvadori B, Baldini E, Bengala C, Pazzagli I, Orlandini C, Danesi R, Fogli S, et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2001;68(2):171–179. doi:10.1023/A:1011945623464.
   PubMed Web of Science ®Google Scholar
• Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009;41(2):77–88. doi:10.1080/03602530902741828.
   PubMed Web of Science ®Google Scholar
• Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78(1):1–12. doi:10.1007/s00280-016-3003-0.
   PubMed Web of Science ®Google Scholar
• Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PloS One. 2010;5(2):e9221. doi:10.1371/journal.pone.0009221
   Google Scholar
• Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PloS One. 2011;6(6):e20740. doi:10.1371/journal.pone.0020740.
   PubMed Web of Science ®Google Scholar
• Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, De Vries J, Boerman O, Schaap N, van der Voort R, Spanholtz J, et al. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rgnull Mice. PloS One. 2013;8(6):e64384. doi:10.1371/journal.pone.0064384.
   PubMed Web of Science ®Google Scholar
• Cany J, van der Waart AB, Spanholtz J, Tordoir M, Jansen JH, van der Voort R, Schaap NM, Dolstra H. Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. Oncoimmunology. 2015;4(7):e1017701. doi:10.1080/2162402X.2015.1017701.
   PubMed Web of Science ®Google Scholar
• Roeven MW, Thordardottir S, Kohela A, Maas F, Preijers F, Jansen JH, Blijlevens NM, Cany J, Schaap N, Dolstra H, et al. The aryl hydrocarbon receptor antagonist stemRegenin1 improves in vitro generation of highly functional natural killer cells from CD34+hematopoietic stem and progenitor cells. Stem Cells Dev. 2015;24(24):2886–2898. doi:10.1089/scd.2014.0597.
   PubMed Web of Science ®Google Scholar
• Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, Van Ijcken WFJ, Heine AAJ, Smid M, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PloS One. 2014;9(9):e103988. doi:10.1371/journal.pone.0103988.
   PubMed Web of Science ®Google Scholar
• Mondal G, Almawash S, Chaudhary AK, Mahato RI. EGFR-targeted cationic polymeric mixed micelles for codelivery of gemcitabine and miR-205 for treating advanced pancreatic cancer. Mol Pharm. 2017;14(9):3121–3133. doi:10.1021/acs.molpharmaceut.7b00355.
   PubMed Web of Science ®Google Scholar
• Kattel K, Mondal G, Lin F, Kumar V, Mahato RI. Biodistribution of self-assembling polymer–gemcitabine conjugate after systemic administration into orthotopic pancreatic tumor bearing mice. Mol Pharm. 2017;14(5):1365–1372. doi:10.1021/acs.molpharmaceut.6b00929.
   PubMed Web of Science ®Google Scholar
• Chitkara D, Mittal A, Behrman SW, Kumar N, Mahato RI. Self-assembling, amphiphilic polymer–gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma. Bioconjug Chem. 2013;24(7):1161–1173. doi:10.1021/bc400032x.
   PubMed Web of Science ®Google Scholar
• Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A. Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther. 2005;12(15):1198–1205. doi:10.1038/sj.gt.3302517.
   PubMed Web of Science ®Google Scholar
• Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A, Kanerva A. Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol. 2008;108(1):166–172. doi:10.1016/j.ygyno.2007.09.013.
   PubMed Web of Science ®Google Scholar
• Garcia-Cremades M, Pitou C, Iversen PW, Troconiz IF. Characterizing gemcitabine effects administered as single agent or combined with carboplatin in mice pancreatic and ovarian cancer xenografts: a semimechanistic pharmacokinetic/pharmacodynamics tumor growth-response model. J Pharmacol Exp Ther. 2017;360(3):445–456. doi:10.1124/jpet.116.237610.
   PubMed Web of Science ®Google Scholar
• Gallo D, Fruscella E, Ferlini C, Apollonio P, Mancuso S, Scambia G. Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP). International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society. 2006;16(1):222–230. doi:10.1111/j.1525-1438.2006.00304.x.
   PubMed Web of Science ®Google Scholar
• Zajchowski DA, Biroc SL, Liu HL, Chesney SK, Hoffmann J, Bauman J, Kirkland T, Subramanyam B, Shen J, Ho E, et al. Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-?-D-arabinofuranosyl) cytosine (4?-thio-FAC) in human pancreatic and ovarian tumor xenograft models. International Journal of Cancer. 2005;114(6):1002–1009. doi:10.1002/ijc.20835.
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, et al. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. J Ovarian Res. 2014;7(1):38. doi:10.1186/1757-2215-7-38.
   PubMedGoogle Scholar
• Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–244.
   PubMedGoogle Scholar
• Veerman G, Ruiz van Haperen VW, Vermorken JB, Noordhuis P, Braakhuis BJM, Pinedo HM, Peters GJ. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol. 1996;38(4):335–342. doi:10.1007/s002800050492.
   PubMed Web of Science ®Google Scholar